Optimer Pharmaceuticals (NASDAQ: OPTR) and Biogen (NASDAQ:BIIB) are both biopharmaceuticals companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Valuation and Earnings

This table compares Optimer Pharmaceuticals and Biogen’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Optimer Pharmaceuticals N/A N/A N/A ($1.74) N/A
Biogen $11.45 billion 5.80 $3.70 billion $16.31 19.26

Biogen has higher revenue and earnings than Optimer Pharmaceuticals. Optimer Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Optimer Pharmaceuticals and Biogen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Optimer Pharmaceuticals 0 0 0 0 N/A
Biogen 0 10 16 1 2.67

Biogen has a consensus price target of $341.96, indicating a potential upside of 8.86%.

Insider & Institutional Ownership

87.7% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Optimer Pharmaceuticals and Biogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Optimer Pharmaceuticals N/A N/A N/A
Biogen 29.44% 38.51% 20.80%

Summary

Biogen beats Optimer Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

Optimer Pharmaceuticals Company Profile

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer’s products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Biogen Company Profile

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive News & Ratings for Optimer Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Optimer Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.